"Observational, Retrospective and Prospective, Non-interventional, Multicentre on the Use of Genomic Testing in the Management of Early Stage HR+/HER2- Breast Cancer" (GIM29-GIMOMIC)
"Observational, Retrospective and Prospective, Non-interventional, Multicentre National Registry-based Study to Collect Information on the Use of Genomic Testing in the Management of Early Stage HR+/HER2- Breast Cancer"
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Mario G Mario Giuliano, MD
- Phone Number: 3762 0817463762
- Email: m.giuliano@unina.it
Study Contact Backup
- Name: GIM29-GIMOMIC S GIM29-GIMOMIC Service
- Phone Number: 1545 +39 089301545
- Email: helpdesk.gim29@oncotech.org
Study Locations
-
-
-
Napoli, Italy, 80131
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
-
Contact:
- Michelino DL Michelino De Laurentiis, MD
- Phone Number: 0432 08117770432
- Email: delauren@breastunit.org;m.delaurentiis@istitutotumori.na.it
-
Napoli, Italy, 80131
- A.O.R.N. "A. Cardarelli"
-
Contact:
- Ferdinando R Ferdinando Riccardi, MD
- Email: ferdinando.riccardi@aocardarelli.it
-
Napoli, Italy, 80131
- Azienda Ospedaliero Universitaria Federico II
-
Contact:
- Mario G Mario Giuliano, MD
- Phone Number: 3762 081 746 3762
- Email: m.giuliano@unina.it
-
Napoli, Italy, 80131
- AORN - Ospedali dei Colli
-
Contact:
- Vincenzo M Vincenzo Montesarchio, MD
- Phone Number: 2855 0817062855
- Email: vincenzo.montesarchio@ospedalideicolli.it
-
Novara, Italy, 28100
- A.O.U. Maggiore della Carita di Novara
-
Contact:
- Alessandra G Alessandra Gennari, MD
- Phone Number: 2296 03213732296
- Email: alessandra.gennari@uniupo.it
-
Pozzuoli, Italy, 80078
- P.O."Santa Maria delle Grazie" di Pozzuoli
-
Contact:
- Angela R Angela Ruggiero, MD
- Email: angela.ruggiero@aslnapoli2nord.it
-
-
AV
-
Avellino, AV, Italy, 83100
- A.O. San Giuseppe Moscati
-
Contact:
- Giuseppe C Giuseppe Colantuoni, MD
- Phone Number: 3945 0825203945
- Email: gicolantuoni@gmail.com
-
-
BG
-
Bergamo, BG, Italy, 24127
- Ospedale Papa Giovanni Xxiii
-
Contact:
- Elena RC Elena Rota Caremoli, MD
- Phone Number: 3694 0352673694
- Email: ecrota@asst-pg23.it
-
-
BO
-
Bologna, BO, Italy, 40138
- Policlinico S. Orsola-Malpighi
-
Contact:
- Claudio Z Claudio Zamagni, MD
- Phone Number: 4548 0512144548
- Email: zamagniclaudio.sper@aosp.bo.it
-
-
BS
-
Brescia, BS, Italy, 25123
- Spedali Civili di Brescia
-
Contact:
- Rebecca P Rebecca Pedersini, MD
- Email: rebecca.pedersini@gmail.com
-
-
CB
-
Termoli, CB, Italy, 86039
- Asrem - Azienda Sanitaria Regionale del Molise
-
Contact:
- Francesco C Francesco Carrozza, MD
- Email: francesco.carrozza@asrem.molise.it
-
-
CE
-
Caserta, CE, Italy, 81100
- Azienda Ospedaliera" Sant'Anna e San Sebastiano"
-
Contact:
- Michele O Michele Orditura, MD
- Phone Number: 2515 0823232515
- Email: michele.orditura@aorncaserta.it
-
-
CN
-
Cuneo, CN, Italy, 12100
- Azienda Ospedaliera S. Croce e Carle
-
Contact:
- Anna Maria V Anna Maria Vandone, MD
- Phone Number: 6350 0171616350
- Email: vandone.a@ospedale.cuneo.it
-
-
FE
-
Ferrara, FE, Italy, 44124
- Azienda Ospedaliero-Universitaria Arcispedale S. Anna
-
Contact:
- Alessio S Alessio Schirone, MD
- Phone Number: 6167 0532236167
- Email: a.schirone@ospfe.it
-
-
FI
-
Firenze, FI, Italy, 50134
- Azienda Ospedaliera Universitaria Careggi
-
Contact:
- Icro M Icro Meattini, MD
- Phone Number: 1828 0552751828
- Email: icro.meattini@unifi.it
-
-
GE
-
Genova, GE, Italy, 16132
- IRCCS Ospedale Policlinico San Martino
-
Contact:
- Davide S. Davide Soldato, MD
- Phone Number: 7300 0105557300
- Email: davide.soldato@hsanmartino.it
-
-
MI
-
Milano, MI, Italy, 20132
- IRCCS Ospedale San Raffaele
-
Contact:
- Luca L Luca Licata, MD
- Phone Number: 6530 0226436530
- Email: licata.luca@hsr.it
-
Milano, MI, Italy, 20141
- Istituto Europeo di Oncologia
-
Contact:
- Giuseppe C Giuseppe Curigliano, MD
- Email: giuseppe.curigliano@ieo.it
-
Rozzano, MI, Italy, 20089
- Irccs Humanitas Research Hospital
-
Contact:
- Alberto Z Alberto Zambelli, MD
- Email: alberto.zambelli@hunimed.eu
-
-
PD
-
Aviano, PD, Italy, 33081
- IRCCS Centro di Riferimento Oncologico (C.R.O.)
-
Contact:
- Fabio P Fabio Puglisi, MD
- Phone Number: 9253 0434659253
- Email: fabio.puglisi@cro.it
-
-
PO
-
Prato, PO, Italy, 59100
- Ospedale S. Stefano
-
Contact:
- Laura B Laura Biganzoli, MD
- Phone Number: 2531 0574802531
- Email: laura.biganzoli@uslcentro.toscana.it
-
-
RE
-
Reggio Emilia, RE, Italy, 42123
- Azienda USL IRCCS di Reggio Emilia
-
-
RM
-
Roma, RM, Italy, 00144
- Istituto Nazionale Tumori Regina Elena
-
Contact:
- Paola M Paola Malaguti, MD
- Phone Number: 6771 0652666771
- Email: paola.malaguti@ifo.it
-
-
RN
-
Rimini, RN, Italy, 47923
- Ospedale infermi di Rimini
-
Contact:
- Lorenzo G Lorenzo Gianni, MD
- Phone Number: 5413 0541705413
- Email: lorenzo.gianni@auslromagna.it
-
-
VI
-
Vicenza, VI, Italy, 36100
- Ospedale San Bortolo di Vicenza
-
Contact:
- Lucia B Lucia Borgato, MD
- Phone Number: 3836 0444753836
- Email: lucia.borgato@aulss8.veneto.it
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- . Age ≥ 18 years
- PS ECOG 0-1
- Histologically confirmed early breast carcinoma with positivity for hormone receptors (ER+ IHC >10%) and HER2 negative (IHC value 0 1+ and/or FISH not-amplified)
Primary resective surgery for early breast cancer with adequate assessment of lymph node status (sentinel lymph node biopsy or complete axillary dissection), with one of the following diagnostic stages:
- T1-3, N0, M0
- T1-3, pN1mic, M0
- T1-3, pN1a, M0
- Indication for adjuvant treatment with endocrine therapy (ET) or chemo endocrine therapy (CET), according to the decision of the reference Breast Unit
Meeting the criteria for "intermediate" risk, i.e., no "low" or "high" risk of recurrence, as defined in the ministerial decree of 18/05/21:
- Low risk defined by at least 5 of the following: G1, T1a-b, KI67 < 15, N neg, ER > 80%
- High risk, defined by at least 4 of the following: G3, T > 2, Ki67 > 30, N pos, ER < 30%
- Indication for genomic test (Oncotype DX®, Mammaprint®, PAM50 Prosigna®, Breast Cancer Index®, EndoPredict®) by the Breast Unit
- Ability to provide written informed consent to participate in the registry study, approved by the local Ethics Committee.
- The patient underwent genomic testing starting from September 2021
Exclusion Criteria:
- Low-risk and High-risk patients as defined in the Ministerial Decree of 18/05/21
- ER negative and/or HER2 positive tumours
- More than 3 lymph nodes involved at clinical/pathological staging
- Invasive tumours <2mm evaluated by local pathologists
- Previous history of breast cancer
- Synchronous breast cancers
- Multifocal tumours
- Metastatic disease
- Contraindications to adjuvant treatments
- Performance status (PS ECOG) > 1 and / or other clinical factors that would make the patient a candidate and unsuitable for systemic adjuvant treatment or have received an exclusive indication for precautionary hormone therapy as part of the Breast Unit collegial assessment.
- Psychiatric diagnosis that may affect the ability to participate in this study
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Prospective cohort
For prospective cohort: genomic tests will be performed on all patients who meet the criteria for access to testing as set out in the Ministerial Decree of 18/05/2021, unless otherwise agreed by the reference Breast Unit, in accordance with the specific diagnostic pathways activated by each site.
|
|
Retrospective cohort
For retrospective cohort: data for patient referred for genomic testing following Ministerial Decree 18/05/2021 will be collected.
The retrospective cohort will contribute to expanding our knowledge of the clinico-pathological characteristics of patients who underwent genomic testing.
This comprehensive understanding of the clinico-pathological profile of patients undergoing genomic testing will enable a more thorough assessment of the clinical dynamics and therapeutic decisions associated with genomic testing results, including the analysis of their possible evolution over the years.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Establishment of a prospective Italian observational registry for the implementation of genomic tests in patients with HR +/HER2- breast cancer
Time Frame: Until November 2026
|
Establishment of a prospective Italian observational registry for the implementation of genomic tests in patients with HR +/HER2- breast cancer at intermediate risk of recurrence after the adoption of the Ministerial Decree of 18/05/2021
|
Until November 2026
|
|
Measurement of the impact of genomic testing on adjuvant treatment choice (CET vs ET only)
Time Frame: Until November 2026
|
Rate of adjuvant treatment choice's change following the genomic test result (Breast Unit's pre-test vs post-test indication)
|
Until November 2026
|
|
Measurement of the impact of genomic testing on adjuvant treatment choice (CET vs ET only)
Time Frame: Until November 2026
|
Saving in adjuvant chemotherapy compared to the pre-test indication
|
Until November 2026
|
|
Measurement of the impact of genomic testing on adjuvant treatment choice (CET vs ET only)
Time Frame: Until November 2026
|
Addition of adjuvant chemotherapy to endocrine therapy alone compared to the pre-test indication
|
Until November 2026
|
|
Measurement of the impact of genomic testing on adjuvant treatment choice (CET vs ET only)
Time Frame: Until November 2026
|
Type of adjuvant treatment the patient actually received
|
Until November 2026
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Record the predominant demographic and clinical characteristics of the patients for whom genomic testing was indicated.
Time Frame: Until November 2026
|
Record the predominant demographic and clinical characteristics of the patients for whom genomic testing was indicated.
|
Until November 2026
|
|
Describe which genomic tests are used and the factors involved in the selection of genomic tests.
Time Frame: Until November 2026
|
Describe which genomic tests are used and the factors involved in the selection of genomic tests.
|
Until November 2026
|
|
Identify any inequalities in access to the genomic tests in different geographical areas of the country.
Time Frame: Until November 2026
|
Identify any inequalities in access to the genomic tests in different geographical areas of the country.
|
Until November 2026
|
|
Record the distribution of demographic and clinical characteristics in the group of patients with changed treatment recommendation compared to the group of patients with unchanged indication after genomic test.
Time Frame: Until November 2026
|
patient age comorbidities, tumour size, number of positive lymph nodes, tumour grade
|
Until November 2026
|
|
Evaluate the impact of the test on the timing of activation of adjuvant treatment
Time Frame: Until November 2026
|
Time from diagnosis to request for genomic test
|
Until November 2026
|
|
Evaluate the impact of the test on the timing of activation of adjuvant treatment
Time Frame: Until November 2026
|
Time from request for the genomic test to result
|
Until November 2026
|
|
Evaluate the impact of the test on the timing of activation of adjuvant treatment
Time Frame: Until November 2026
|
Time from test result to activation of adjuvant chemotherapy, if indicated
|
Until November 2026
|
|
Evaluate the impact of the test on the timing of activation of adjuvant treatment
Time Frame: Until November 2026
|
Time from diagnosis to activation of adjuvant chemotherapy, if indicated
|
Until November 2026
|
|
Analyse the prescriptive adequacy and the compliance
Time Frame: Until November 2026
|
With the inclusion criteria for genomic tests.
|
Until November 2026
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- GIM29-GIMOMIC
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.